Aducanumab

ALZ-NET: examining novel approved treatments in the real-world

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Lecanemab vs aducanumab

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Future direction for anti-amyloid immunotherapies

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Lowering blood pressure as a treatment for VCID

Impact of Alzheimer’s disease treatments on apathy

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Is amyloid lowering still a valid approach in Alzheimer’s disease?

Potential of anti-amyloid drugs for treating Alzheimer’s disease

Important developments in dementia: biomarkers & clinical trials

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab